Add-on treatment with DeltEx DRI, a cell therapy being developed by In8bio, may help prolong survival in people with glioblastoma, an aggressive form of…
News
A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…
Treatment with a regimen based on the experimental therapy mezigdomide reduced the risk of disease progression or death by more than 50% compared with standard…
The U.S. Food and Drug Administration (FDA) has granted fast-track designation to STX-0712, an experimental therapy Solu Therapeutics is developing to treat chronic myelomonocytic…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental delivery method for the chemotherapy oxaliplatin as a potential treatment…
An experimental therapy designed to mimic vitamin B12 and deliver a toxic molecule to tumor cells showed promise as a potential treatment for an aggressive…
The experimental cancer vaccine Tedopi (OSE2101), when given in combination with the approved injection therapy Keytruda (pembrolizumab), outperforms standard-of-care treatment in delaying disease…
For World Blood Cancer Day this May 28 — a day when advocates around the globe join forces to raise awareness…
Following “encouraging findings” from an early study, Can-Fite Biopharma is planning a clinical trial to test…
A Phase 1 clinical trial testing TLX101-Tx, Telix Pharmaceuticals‘ experimental treatment for glioblastoma (an aggressive form of glioma), has completed enrollment. The study,…
